Researchers develop new tool to protect against HIV infection

Researchers at the University of Waterloo have developed a vaginal implant that could prevent women from contracting HIV. The implant works by reducing the number of T cells that can be targeted by HIV in the genital tract.

Credit: crystal light/Shutterstock.com

HIV targets and infects activated T cells, a subset of lymphocytes that comprise the adaptive immune system. T cells are activated when the virus enters the body. Inactive T cells, known as “immune quiescent” T cells, are not susceptible to infection.

We know that some drugs taken orally never make it to the vaginal tract, so this implant could provide a more reliable way to encourage T cells not to respond to infection and therefore more reliably and cheaply prevent transmission."

Professor Emmanuel Ho, University of Waterloo

"What we don't know yet is if this can be a stand-alone option for preventing HIV transmission or if it might be best used in conjunction with other prevention strategies. We aim to answer these questions with future research," he added.

The implant was inspired by previous research that involved female sex workers in Kenya. Ho and research partner Keith Fowke from the University of Manitoba, found that many of the sex workers had not contracted HIV, despite having had sex with HIV-positive clients. They later found that these women had T cells that were naturally immune quiescent.

Ho and Fowke wondered whether it was possible to induce immune quiescence using medication that was more likely to reach the infection site.

"By delivering the medication exactly where it's needed, we hoped to increase the chances of inducing immune quiescence," says Ho.

As reported in the Journal of Controlled Release, the implant is comprised of a hollow tube made of porous material and held in place by two flexible arms.

The tube contains an anti-malarial agent that is slowly disseminated through the porous material and absorbed by the walls of the vaginal tract.

When the team tested the implant in an animal model, T cell activation was significantly reduced, suggesting that the vaginal tract was demonstrating an immune quiescent state.

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2019, June 19). Researchers develop new tool to protect against HIV infection. News-Medical. Retrieved on December 19, 2024 from https://www.news-medical.net/news/20180416/Researchers-develop-new-tool-to-protect-against-HIV-infection.aspx.

  • MLA

    Robertson, Sally. "Researchers develop new tool to protect against HIV infection". News-Medical. 19 December 2024. <https://www.news-medical.net/news/20180416/Researchers-develop-new-tool-to-protect-against-HIV-infection.aspx>.

  • Chicago

    Robertson, Sally. "Researchers develop new tool to protect against HIV infection". News-Medical. https://www.news-medical.net/news/20180416/Researchers-develop-new-tool-to-protect-against-HIV-infection.aspx. (accessed December 19, 2024).

  • Harvard

    Robertson, Sally. 2019. Researchers develop new tool to protect against HIV infection. News-Medical, viewed 19 December 2024, https://www.news-medical.net/news/20180416/Researchers-develop-new-tool-to-protect-against-HIV-infection.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Affordability and supply remain critical to the success of long-lasting HIV drug